This project aims to provide a new treatment for the large number of adolescents with severe obesity who do not respond to current best practice in paediatric obesity treatment - lifestyle treatment. Based on our previous work revealing the important role of brain-gut signaling in regulating appetite and satiety, and our preclinical studies and phase IIa trial in adults with obesity, we attempt to fill this treatment gap by testing the efficacy of a novel treatment - Endoscopic Injection of Botulinum toxin A for Obesity (EIBO) - in a multinational, randomized, double blind, placebo-controlled phase II clinical trial.
The present project is an extension of a submitted EU-proposal; "Repurposing Endoscopic injections of Botulinum toxin A in treatment of adolescents with severe obesity (EIBO)" (Topic H2020?SCI-PM-09-2016) with NTNU as coordinator of the consortium. The present extension lies in A) establishing a robust cooperation between the specialist - and municipality health services to strengthen the effect of the new treatment, and B) to establish an algorithm for prediction of response to the new EIBO treatment in order to maximize the success rate for those who are treated.
If the original project is not obtaining funding by EU (known by aug. 2016) the consortium intend to perform the project within the frames of separate national funding. The concepts of the present project is not influenced by the outcome of the EU proposal but in case of refusal more patients need to be included in Norway to secure the sufficient number of patient.
BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering